Pre Next

[1] ZHOUHaiwang, CHENXinsheng, DUSisi, et al. ClinicalObservationof41COVID-19RecurrencePatientsTreatedwithChineseMedicineCombinedwithMoxibustion [J]. Modern Traditional Chinese Medicine, 2021, (03): 55-59. [doi: 10.13424/j.cnki.mtcm.2021.03.011]

Copy

ClinicalObservationof41COVID-19RecurrencePatientsTreatedwithChineseMedicineCombinedwithMoxibustion

Modern Traditional Chinese Medicine[ISSN: 1006-6977/ CN: 61-1281/TN] Volumes & Issues: 2021 03 pagination: 55-59 Column: Publication date: 2021-05-20

Article number:: 1672-0571(2021)03-0055-05

Author(s):: ZHOUHaiwang; CHENXinsheng; DUSisi; GONGJianzhong; CHENGZhang; SONGHongwen; DUZhenfan; E’zhouHospitalofTraditionalChineseMedicine,HubeiE’zhou436000,China

Keywords:: NewCoronaviruspneumonia; COVID-19; Chinesemedicine; Moxibustion; Recurrence

ZTFLH:: R254

DOI:: 10.13424/j.cnki.mtcm.2021.03.011

Code:: A

Abstract:: Objective:ToobservethetherapeuticeffectofChinesemedicinecombinedwithMoxibustionon41recurrencecasesofCOVID-19.Methods:Accordingtothesymptomsandsigns,combinedwiththerecoverytreatmentplanof“COVID-19recoveryperiodguidanceadvice(Trial)”,allpatientsweredividedintotwobasicsyndromes:“lungspleenQideficiency”and“QiYinDeficiency”.Theyweregivenprescriptions,andweretreatedwithmoxibustionfor2weeks.Theoverallcurativeeffect(self-madestandard)wasevaluated,andtherecoveryrateofsinglesymptom,thechangeofVASscore,thechangeoftonguepictureandthenegativeconversionratewerecomparedbeforeandaftertreatment.Results:After2weeksoftreatment,thecurerateofpatientswas34.15%,andthetotaleffectiveratewas87.80%;thecureratesofcommonsinglesymptoms:pharyngealdiscomfort,insomnia,abdominaldistensionwere58.62%,60.0%,69.23%,respectively,withsignificantdifference(p<0.05);somepatientssymptomsdidnotdisappearcompletely,buttheVASscoresofpharyngealdiscomfort,insomnia,chesttightnesswerealsosignificantlylowerthanbefore (p<0.05).Aftertreatment,thenumberofteethtracetongueandwhitegreasyfurdecreasedsignificantly,andthenumberofthinwhitefurincreasedsignificantly(p<0.05);Asfortheeffectofturningnegativeinrecurrencerate,33cases(80.48%)turnednegativein1week,6cases(14.63%)turnednegativein2weeks,andthetotalturningnegativeratewas95.11%.Conclusion:TraditionalChinesemedicinecombinedwithmoxibustioncannotonlysignificantlyimprovetheclinicalsymptomsofrecurrencepatients,butalsomakethetongueimagefromabnormaltonormal.Atthesametime,ithasapositiveeffectonpromotingnucleicacidtoturnnegativeagain,whichisworthyofclinicalreference

References:

[1]李晓东,刘保延,王宜,等.关于《新型冠状病毒肺炎恢复期中医康复指导建议(试行)》的解读[J].中医杂志,2020,61(11):928-934.
[2]詹志来,刘佳,杨伟,等.基于病例分析的中医药治疗新型冠状病毒肺炎疗效评价标准的探索研究[J].中医杂志,2020,61(12):1013-1023.
[3]国家卫生健康委办公厅,国家中医药管理局办公室.关于印发新型冠状病毒肺炎诊疗方案(试行第六版)的通知 [EB/OL].[2020-02-18]http://www.gov.cn/ zhengce/zhengceku/2020,02(19)content.5480948.htm.
[4]仝小林,李修洋,赵林华,等.从“寒湿疫”角度探讨新型冠状病毒肺炎的中医药防治策略[J].中医杂志,2020,61(6):465-470.
[5]刘豪,丁中华,张思超.浅论温病发病机制及其传变特点[J].世界最新医学信息文摘,2019,19(98):308-309,312.
[6]张景岳.杂证谟 [M].北京:中国医药科技出版社,2017:78,87,88.
[7]吕丰.艾灸物理特性研究[D].武汉:中南民族大学,2015:6.
[8]张昕洋,郭子宁.舌苔与病?证探讨[J].北京中医药大学学报,2015,38(6):373-376.
[9]李筱,冯敖梓,马文,等.新型冠状病毒肺炎中医证候学的系统评价和 Meta分析[J].世界中医药,2020,15(3):305-309,314.
[10]张炳厚.医林怪杰张炳厚.北京:中国中医药出版社,2016:272
[11]王彦晖.中医湿病学.北京:人民卫生出版社,1997:81-82.
[12]张圆,王玉光,程海英.新型冠状病毒肺炎出院患者中医康复治疗思路与方法[J].北京中医药.2020,39(3)227-229.
[13]郑立夫,郑碧云,唐纯志.从脏腑致病角度分析导引在新冠肺炎防治中的应用[J].中医学报.2020,35(5)916-919
[14]蒋凡,彭家玺,袁成凯,等.中医情志疗法防治新型冠状病毒肺炎[J/OL].中医学报.1-7[2020-02-27].
[15]徐耀,雷应,冉明山,等.张振宇谈从 SARS到 COVID-19出院患者肺功能中医非药物康复的思路探讨[J].按摩与康复医学,2020,11(11):8-9,13.
[16]张燕.从中医“治未病”理论谈新型冠状病毒肺炎(COVID-19)的中医预防[J].中医药信息.2020,37(2):5-8
[17]罗丹,张海明,于兆民,等.中医“治未病”理论指导新型冠状病毒肺炎防治的思考[J].陕西中医药大学学报.2020,43(2):5-7.
[18]周洪立,陈海彬,周红光,等.中医“治未病”思想在防控新型冠状病毒感染肺炎中的应用[J].河南中医,2020,40(3):332-335
[19]杨月欣,杨晓光,马爱国,等.新型冠状病毒肺炎防治营养膳食指导建议[J].营养学报,2020,42(1):1-2.
[20]刘理想,胡镜清,林明欣,等.中医学防控疫病历史回顾与思考[J].中国中医基础医学杂志,2020,26(3):281-284.

Memo

基金项目：国家重点研发计划（２０２０ＹＦＣ０８４５０００）；鄂州市新型肺炎应急科技项目（ＥＺ０４００１２０２００００５）；全国中医优秀临床人才研修项目［２０１７］２４

Last Update: 2021-06-08